| |  Online-Ressource |
|---|
| Verfasst von: | Reece, Donna E. [VerfasserIn]  |
|---|
| | Hegenbart, Ute [VerfasserIn] |
|---|
| | Sanchorawala, Vaishali [VerfasserIn] |
|---|
| | Merlini, Giampaolo [VerfasserIn] |
|---|
| | Palladini, Giovanni [VerfasserIn] |
|---|
| | Bladé, Joan [VerfasserIn] |
|---|
| | Fermand, Jean-Paul [VerfasserIn] |
|---|
| | Hassoun, Hani [VerfasserIn] |
|---|
| | Heffner, Leonard [VerfasserIn] |
|---|
| | Vescio, Robert A. [VerfasserIn] |
|---|
| | Liu, Kevin [VerfasserIn] |
|---|
| | Enny, Christopher [VerfasserIn] |
|---|
| | Esseltine, Dixie-Lee [VerfasserIn] |
|---|
| | van de Velde, Helgi [VerfasserIn] |
|---|
| | Cakana, Andrew [VerfasserIn] |
|---|
| | Comenzo, Raymond L. [VerfasserIn] |
|---|
| Titel: | Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis |
|---|
| Titelzusatz: | results of a phase 1/2 study |
|---|
| Verf.angabe: | Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Robert A. Vescio, Kevin Liu, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, and Raymond L. Comenzo |
|---|
| E-Jahr: | 2011 |
|---|
| Jahr: | July 28, 2011 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 14.09.2022 |
|---|
| Titel Quelle: | Enthalten in: Blood |
|---|
| Ort Quelle: | Washington, DC : American Society of Hematology, 1946 |
|---|
| Jahr Quelle: | 2011 |
|---|
| Band/Heft Quelle: | 118(2011), 4, Seite 865-873 |
|---|
| ISSN Quelle: | 1528-0020 |
|---|
| Abstract: | This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase 1 testing (1.6 mg/m2 once weekly [days 1, 8, 15, and 22; 35-day cycles]; 1.3 mg/m2 twice weekly [days 1, 4, 8, and 11; 21-day cycles]). Among all 70 patients enrolled in the study, 44% had ≥ 3 organs involved, including 73% and 56% with renal and cardiac involvement. In the 1.6 mg/m2 once-weekly and 1.3 mg/m2 twice-weekly groups, the hematologic response rate was 68.8% and 66.7% (37.5% and 24.2% complete responses, respectively); median time to first/best response was 2.1/3.2 and 0.7/1.2 months, and 78.8% and 75.5% had response durations of ≥ 1 year, respectively. One-year hematologic progression-free rates were 72.2% and 74.6%, and 1-year survival rates were 93.8% and 84.0%, respectively. Outcomes appeared similar in patients with cardiac involvement. Among all 70 patients, organ responses included 29% renal and 13% cardiac responses. Rates of grade ≥ 3 toxicities (79% vs 50%) and discontinuations/dose reductions (38%/53% vs 28%/22%) resulting from toxicities appeared higher with 1.3 mg/m2 twice-weekly versus 1.6 mg/m2 once-weekly dosing. Both bortezomib dose schedules represent active, well-tolerated regimens in relapsed AL amyloidosis. This study was registered at www.clinicaltrials.gov as #NCT00298766. |
|---|
| DOI: | doi:10.1182/blood-2011-02-334227 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1182/blood-2011-02-334227 |
|---|
| | DOI: https://doi.org/10.1182/blood-2011-02-334227 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1816624454 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis / Reece, Donna E. [VerfasserIn]; July 28, 2011 (Online-Ressource)
